Home > Healthcare > Hairy Cell Leukemia Market

Hairy Cell Leukemia Market Share

Report ID: GMI8334
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Hairy Cell Leukemia Market Share

The hairy cell leukemia industry comprises companies such as Amgen Inc, AstraZeneca, F. Hoffmann-La Roche Ltd, and Merck KGaA. These are significant players, with well-established product portfolios. Companies adopt several inorganic growth strategies to maintain their market share.

Hairy Cell Leukemia Market Companies

Prominent players operating in the hairy cell leukemia industry include:

Amgen Inc.
Astellas Pharma Inc.
AstraZeneca plc
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer Inc.
Takeda Pharmaceutical Company Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Hairy cell leukemia market size was USD 130.7 million in 2023 and is expected to register 6.5% CAGR from 2024-2032 owing to the increasing incidence rates of blood related cancers, advancements in diagnosis and rare disease treatment options, and emerging oncology therapies worldwide.

The chemotherapy segment held 65.2% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to being a standard treatment offer and acting as a first-line therapy for newly diagnosed HCL patients.

Asia Pacific hairy cell leukemia industry garnered 43.6% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of a large population and high incidence of leukemia cases in the region.

Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited, are some of the major hairy cell leukemia companies worldwide.